Serum interleukin-23 level in rheumatoid arthritis patients: Relation to disease activity and severity
| Autor: | Abeer Mohamed El-Shafey, Mazen M. Alsheikh, Enas T. El-Desoky, Heba H. Gawish |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
lcsh:Immunologic diseases. Allergy
030203 arthritis & rheumatology medicine.medical_specialty medicine.diagnostic_test biology business.industry Physical examination medicine.disease Gastroenterology Disease activity 03 medical and health sciences 0302 clinical medicine Rheumatology Erythrocyte sedimentation rate Internal medicine Rheumatoid arthritis medicine biology.protein Interleukin 23 Rheumatoid factor Medical history 030212 general & internal medicine Antibody lcsh:RC581-607 business |
| Zdroj: | Egyptian Rheumatologist, Vol 41, Iss 2, Pp 99-103 (2019) |
| ISSN: | 1110-1164 |
| Popis: | Aim of the work: The aim of this study was to evaluate interleukin-23 (IL-23) level in the sera of rheumatoid arthritis (RA) patients and to determine its relation with disease activity and severity. Patients and methods: This study was carried out on 40 RA patients and 40 healthy control subjects. All patients were subjected to full history taking, thorough clinical examination, radiological and laboratory investigations including C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), rheumatoid factor (RF), anti-cyclic-citrullinated peptide (anti-CCP) antibodies. Serum IL-23 was measured by enzyme-linked immunosorbent assay. Disease activity score (DAS-28) and rheumatoid arthritis severity scale (RASS) were assessed. Results: Patient's mean age was 43.3 ± 10.4 years and they were 37 females and 3 males. The mean disease duration of the patients was 4.98 ± 4.1 years (1–15 years) with a mean DAS-28 of 4.8 ± 1.2 (2.4–7.6) and RASS of 41.1 ± 16.9 (16.7–85). The mean IL-23 serum level was significantly higher in RA patients (67.6 ± 39.2 pg/ml) compared to the control (37.7 ± 15.6 pg/ml) (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect